FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385705997> ?p ?o ?g. }

• W4385705997 endingPage "e2165883" @default.
• W4385705997 startingPage "e2165883" @default.
• W4385705997 abstract "Topic: 32. Platelet disorders Background: As of 2021, the thrombopoietin receptor agonist (TPO-RA) romiplostim is licensed for adults with immune thrombocytopenia (ITP) across all disease phases, including duration ≤1 year refractory to first-line treatments. While aligned with treatment guidelines, real-world UK data on this indication are lacking. Aims: To assess the response to romiplostim, we performed a retrospective UK-wide study of real-world treatment patterns in adults with primary ITP ≤1 year from diagnosis between 2 July 2015 and 23 March 2020. Methods: Recruited patients were divided into those who either did (Group 1) or did not (Group 2) receive romiplostim during the first year from diagnosis. TPO-RAs, including eltrombopag, could be received in either group after the first year (excluding eltrombopag in the first year). All efficacy and safety analyses were descriptive. Results: Seventy-eight patients enrolled at seven UK sites; Group 1 (n=13) 62% female, median (min-max) platelets 4 (2-44)×109/L and Group 2 (n=65) 59% female, median (min-max) platelets 7 (0-108)×109/L (Table). In Group 1, romiplostim was initiated (off-license) at a median of 6 weeks with a median treatment duration of 63 weeks; 2/13 received romiplostim first-line and 11/13 as the second treatment or later. Romiplostim treatment continued in 8/13 patients at study end. Other treatments in Group 1 in more than one patient included: prednisolone (n=11), mycophenolate mofetil (MMF, n=5), IVIg (n=4), and rituximab (n=3). In Group 2, two patients (3%) received no treatment; 33 patients (51%) received corticosteroids ± IVIg ± tranexamic acid only without further escalation; 26 patients (40%) required MMF or rituximab. In the second year, six patients (9%) in Group 2 required a TPO-RA. The median treatment duration was shorter for Group 1 vs 2 for prednisolone (3 vs 10 weeks for those discontinuing prednisolone) and MMF (13 vs 39 weeks). By the end of the 2-year treatment period, median (interquartile range) platelet counts had increased to 157 (81-275) and 122 (81-202)×109/L in Groups 1 and 2, respectively. During the observation period in Groups 1 and 2, respectively, bleeding episodes occurred in 54% and 63% of patients, and rescue therapies were required by 39% and 31% of patients. The mean number of rescue therapies/patient was 0.6 and 0.8 in Groups 1 and 2, respectively. Thromboembolic events occurred in one patient in each group (Group 1: sub-acute left lower limb arterial ischemia; Group 2: stroke).Summary/Conclusion: These findings support further exploring the earlier use of romiplostim for adult patients with primary ITP. Keywords: Immune thrombocytopenia (ITP), Thrombopoietin (TPO), Thrombocytopenia, Platelet" @default.
• W4385705997 created "2023-08-10" @default.
• W4385705997 creator A5004886985 @default.
• W4385705997 creator A5008779503 @default.
• W4385705997 creator A5024708495 @default.
• W4385705997 creator A5026356846 @default.
• W4385705997 creator A5038274559 @default.
• W4385705997 creator A5039595444 @default.
• W4385705997 creator A5063777404 @default.
• W4385705997 creator A5070399571 @default.
• W4385705997 creator A5076530342 @default.
• W4385705997 creator A5086810447 @default.
• W4385705997 creator A5089578564 @default.
• W4385705997 date "2023-08-01" @default.
• W4385705997 modified "2023-09-27" @default.
• W4385705997 title "PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA" @default.
• W4385705997 doi "https://doi.org/10.1097/01.hs9.0000977136.21658.83" @default.
• W4385705997 hasPublicationYear "2023" @default.
• W4385705997 type Work @default.
• W4385705997 citedByCount "0" @default.
• W4385705997 crossrefType "journal-article" @default.
• W4385705997 hasAuthorship W4385705997A5004886985 @default.
• W4385705997 hasAuthorship W4385705997A5008779503 @default.
• W4385705997 hasAuthorship W4385705997A5024708495 @default.
• W4385705997 hasAuthorship W4385705997A5026356846 @default.
• W4385705997 hasAuthorship W4385705997A5038274559 @default.
• W4385705997 hasAuthorship W4385705997A5039595444 @default.
• W4385705997 hasAuthorship W4385705997A5063777404 @default.
• W4385705997 hasAuthorship W4385705997A5070399571 @default.
• W4385705997 hasAuthorship W4385705997A5076530342 @default.
• W4385705997 hasAuthorship W4385705997A5086810447 @default.
• W4385705997 hasAuthorship W4385705997A5089578564 @default.
• W4385705997 hasBestOaLocation W43857059971 @default.
• W4385705997 hasConcept C109159458 @default.
• W4385705997 hasConcept C126322002 @default.
• W4385705997 hasConcept C141071460 @default.
• W4385705997 hasConcept C187212893 @default.
• W4385705997 hasConcept C2776915898 @default.
• W4385705997 hasConcept C2777863708 @default.
• W4385705997 hasConcept C2778713057 @default.
• W4385705997 hasConcept C2779338263 @default.
• W4385705997 hasConcept C2780588981 @default.
• W4385705997 hasConcept C2780653079 @default.
• W4385705997 hasConcept C28328180 @default.
• W4385705997 hasConcept C2993327898 @default.
• W4385705997 hasConcept C54355233 @default.
• W4385705997 hasConcept C71924100 @default.
• W4385705997 hasConcept C86803240 @default.
• W4385705997 hasConcept C89560881 @default.
• W4385705997 hasConceptScore W4385705997C109159458 @default.
• W4385705997 hasConceptScore W4385705997C126322002 @default.
• W4385705997 hasConceptScore W4385705997C141071460 @default.
• W4385705997 hasConceptScore W4385705997C187212893 @default.
• W4385705997 hasConceptScore W4385705997C2776915898 @default.
• W4385705997 hasConceptScore W4385705997C2777863708 @default.
• W4385705997 hasConceptScore W4385705997C2778713057 @default.
• W4385705997 hasConceptScore W4385705997C2779338263 @default.
• W4385705997 hasConceptScore W4385705997C2780588981 @default.
• W4385705997 hasConceptScore W4385705997C2780653079 @default.
• W4385705997 hasConceptScore W4385705997C28328180 @default.
• W4385705997 hasConceptScore W4385705997C2993327898 @default.
• W4385705997 hasConceptScore W4385705997C54355233 @default.
• W4385705997 hasConceptScore W4385705997C71924100 @default.
• W4385705997 hasConceptScore W4385705997C86803240 @default.
• W4385705997 hasConceptScore W4385705997C89560881 @default.
• W4385705997 hasIssue "S3" @default.
• W4385705997 hasLocation W43857059971 @default.
• W4385705997 hasLocation W43857059972 @default.
• W4385705997 hasOpenAccess W4385705997 @default.
• W4385705997 hasPrimaryLocation W43857059971 @default.
• W4385705997 hasRelatedWork W10143852 @default.
• W4385705997 hasRelatedWork W2026416582 @default.
• W4385705997 hasRelatedWork W2034419973 @default.
• W4385705997 hasRelatedWork W2182308824 @default.
• W4385705997 hasRelatedWork W2397160689 @default.
• W4385705997 hasRelatedWork W2480828208 @default.
• W4385705997 hasRelatedWork W2784525383 @default.
• W4385705997 hasRelatedWork W2922116545 @default.
• W4385705997 hasRelatedWork W3028684527 @default.
• W4385705997 hasRelatedWork W74871909 @default.
• W4385705997 hasVolume "7" @default.
• W4385705997 isParatext "false" @default.
• W4385705997 isRetracted "false" @default.
• W4385705997 workType "article" @default.